From The AIS Report on Blue Cross and Blue Shield Plans - Despite strong evidence that some women with early stage breast cancer can achieve the same results with a shorter course of treatment, many radiation oncologists haven’t changed their treatment regimens, according to the results of a study published Dec. 17 in the Journal of the American Medical Association (JAMA). The study — conducted by the University of Pennsylvania, Anthem, Inc. and its outcomes research subsidiary, HealthCore — is the first to review related practice patterns to determine whether physicians are following the latest medical evidence. Read more
From The AIS Report on Blue Cross and Blue Shield Plans - Blues plan operator Anthem, Inc. is teaming up with pharma giants Boehringer Ingelheim (BI) and Eli Lilly and Co. to identify gaps in care and explore real-world effects of prescription drugs through two separate five-year research agreements. Read more
From Health Plan Week - A top Cigna Corp. pharmacy management executive tells HPW the insurer’s “real-world” monitoring of its members with hepatitis C who have been treated with a prescription combination including the drug Sovaldi had a 91.1% cure rate, or sustained virologic response (SVR), when measured after a 12-week treatment regime. Read more
Check out all of the benefits, sample issues & more!